Oncolytics Biotech Reports Pelareorep-Driven HPV Immune Responses in Anal Cancer Study
The company reported increased HPV-specific immune responses in patients with squamous cell anal cancer.
Related stories
Ronesans Gayrimenkul Q3 Revenue Rises to 4.8 Billion Lira
Q3 revenue was 4.8 billion lira, compared with 4.0 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
Ronesans Gayrimenkul Yatirim Reports Q3 Net Profit of 5.3 Billion Lira
Net profit was 5.3 billion lira, compared with 11.6 billion lira a year earlier.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
Google invertirá USD 15.000 millones en Malasia
La inversión prevista contempla centros de datos, energía y agua.
M impact | EQUITY | Nov 04, 2026, 03:34 PM UTC
General Motors shares hit record high, up 4%
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
SolarEdge Reports Q3 Revenue of $326.1 Million, Adjusted EPS of $0.29
Third-quarter revenue was $326.1 million, in line with the midpoint of prior guidance. Adjusted EPS was $0.29 versus FactSet consensus of $0.04. SolarEdge forecast fourth-quarter r
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC
Kempower Reports Q3 Revenue Decline and Lowers 2026 Guidance
Kempower reported a 10% revenue decline and negative operative EBIT in Q3 2026, citing weakening charging investment. It lowered full-year 2026 guidance, while reporting a €128 mil
M impact | EQUITY | Nov 04, 2026, 03:33 PM UTC